1. Langlois F, Varlamov EV, Fleseriu M. Hypophysitis, the growing spectrum of a rare
pituitary disease. J Clin Endocrinol Metab (2022) 107:10–28. doi: 10.1210/clinem/dgab672
20. Yano S, Ashida K, Sakamoto R, Sakaguchi C, Ogata M, Maruyama K, et al.
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint
inhibitor-induced secondary adrenal insufficiency. Eur J Cancer (2020) 130:198–203.
doi: 10.1016/j.ejca.2020.02.049
2. Prodam F, Caputo M, Mele C, Marzullo P, Aimaretti G. Insights into non-classic
and emerging causes of hypopituitarism. Nat Rev Endocrinol (2021) 17:114–29.
doi: 10.1038/s41574-020-00437-2
21. Kobayashi T, Iwama S, Sugiyama D, Yasuda Y, Okuji T, Ito M, et al. Antipituitary antibodies and susceptible human leukocyte antigen alleles as predictive
biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. J
Immunother Cancer (2021) 9:e002493. doi: 10.1136/jitc-2021-002493
3. Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticotrophin deficiency.
Pituitary (2006) 9:289–95. doi: 10.1007/s11102-006-0408-5
4. Hannon MJ, O’Halloran DJ. Isolated acquired ACTH deficiency and primary
hypothyroidism: a short series and review. Pituitary (2011) 14:358–61. doi: 10.1007/
s11102-008-0164-9
22. Heaney AP, Sumerel B, Rajalingam R, Bergsneider M, Yong WH, Liau LM. HLA
markers DQ8 and DR53 are associated with lymphocytic hypophysitis and may aid in
differential diagnosis. J Clin Endocrinol Metab (2015) 100:4092–7. doi: 10.1210/jc.20152702
5. Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, et al. Isolated
autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the
dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun
Rev (2020) 19:102454. doi: 10.1016/j.autrev.2019.102454
23. Lindsay CR, Shaw EC, Moore DA, Rassl D, Jamal-Hanjani M, Steele N, et al.
Large cell neuroendocrine lung carcinoma: consensus statement from The British
Thoracic Oncology Group and the Association of Pulmonary Pathologists. Br J Cancer
(2021) 125:1210–6. doi: 10.1038/s41416-021-01407-9
6. Iglesias P, Sá nchez JC, Dı́ez JJ. Isolated ACTH deficiency induced by cancer
immunotherapy: a systematic review. Pituitary (2021) 24:630–43. doi: 10.1007/s11102021-01141-8
24. Toivanen S, Leijon H, Arola A, Soinio M, Hämäläinen PO, Metso S, et al.
Characteristics and outcomes of the Finnish ectopic ACTH syndrome cohort.
Endocrine (2021) 74:387–95. doi: 10.1007/s12020-021-02768-0
7. Sugiura M, Hashimoto A, Shizawa M, Tsukada M, Maruyama S, Ishido T, et al.
Heterogeneity of anterior pituitary cell antibodies detected in insulin-dependent diabetes
mellitus and adrenocorticotropic hormone deficiency. Diabetes Res (1986) 3:111–4.
25. Takahashi Y. Paraneoplastic autoimmune hypophysitis: a novel form of
paraneoplastic endocrine syndrome. Endocr J (2023) 70:559–65. doi: 10.1507/
endocrj.EJ23-0050
8. Sauter NP, Toni R, McLaughlin CD, Dyess EM, Kritzman J, Lechan RM. Isolated
adrenocorticotropin deficiency associated with an autoantibody to a corticotroph
antigen that is not adrenocorticotropin or other proopiomelanocortin-derived
peptides. J Clin Endocrinol Metab (1990) 70:1391–7. doi: 10.1210/jcem-70-5-1391
26. Hao L, Zhao X, Zhang B, Li C, Wang C. Positive expression of proopiomelanocortin (POMC) is a novel independent poor prognostic marker in
surgically resected non-small cell lung cancer. Tumour Biol (2015) 36:1811–7.
doi: 10.1007/s13277-014-2784-1
9. Fujita Y, Bando H, Iguchi G, Iida K, Nishizawa H, Kanie K, et al. Clinical
heterogeneity of acquired idiopathic isolated adrenocorticotropic hormone deficiency.
Front Endocrinol (2021) 12:578802. doi: 10.3389/fendo.2021.578802
27. Messager M, Carrière C, Bertagna X, de Keyzer Y. RT-PCR analysis of
corticotroph-associated genes expression in carcinoid tumours in the ectopic-ACTH
syndrome. Eur J Endocrinol (2006) 154:159–66. doi: 10.1530/eje.1.02077
10. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system.
N Engl J Med (2003) 349:1543–54. doi: 10.1056/NEJMra023009
11. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and
treatment. Mayo Clin Proc (2010) 85:838–54. doi: 10.4065/mcp.2010.0099
28. Harno E, Gali Ramamoorthy T, Coll AP, White A. POMC: the physiological
power of hormone processing. Physiol Rev (2018) 98:2381–430. doi: 10.1152/
physrev.00024.2017
12. Takahashi Y. The novel concept of “Onco-Immuno-Endocrinology” led to the
discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”. Best Pract
Res Clin Endocrinol Metab (2022) 36:101663. doi: 10.1016/j.beem.2022.101663
29. Yamamoto M, Iguchi G, Bando H, Kanie K, Hidaka-Takeno R, Fukuoka H, et al.
Autoimmune pituitary disease: new concepts with clinical implications. Endocr Rev
(2020) 41:bnz003. doi: 10.1210/endrev/bnz003
13. Bando H, Iguchi G, Kanie K, Nishizawa H, Matsumoto R, Fujita Y, et al. Isolated
adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome.
Pituitary (2018) 21:480–9. doi: 10.1007/s11102-018-0901-7
30. Raffin-Sanson ML, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide
precursor with multiple functions: from physiology to pathological conditions. Eur J
Endocrinol (2003) 149:79–90. doi: 10.1530/eje.0.1490079
14. Kanie K, Iguchi G, Bando H, Urai S, Shichi H, Fujita Y, et al. Mechanistic insights into
immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Cancer Immunol Immunother (2021) 70:3669–77. doi: 10.1007/s00262-021-02955-y
31. Imura H, Sparks LL, Grodsky GM, Forsham PH. Immunologic studies of
adrenocorticotropic hormone (ACTH): dissociation of biologic and immunologic
activities. J Clin Endocrinol Metab (1965) 25:1361–9. doi: 10.1210/jcem-25-10-1361
15. Bando H, Kanie K, Takahashi Y. Paraneoplastic autoimmune hypophysitis: An
emerging concept. Best Pract Res Clin Endocrinol Metab (2022) 36:101601.
doi: 10.1016/j.beem.2021.101601
32. Iwama S, Arima H. Anti-pituitary antibodies as a marker of autoimmunity in
pituitary glands. Endocr J (2020) 67:1077–83. doi: 10.1507/endocrj.EJ20-0436
33. Bellastella G, Rotondi M, Pane E, Dello Iacovo A, Pirali B, Dalla Mora L, et al.
Predictive role of the immunostaining pattern of immunofluorescence and the titers of
antipituitary antibodies at presentation for the occurrence of autoimmune
hypopituitarism in patients with autoimmune polyendocrine syndromes over a fiveyear follow-up. J Clin Endocrinol Metab (2010) 95:3750–7. doi: 10.1210/jc.2010-0551
16. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al.
Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice
guideline. J Clin Endocrinol Metab (2016) 101:3888–921. doi: 10.1210/jc.2016-2118
17. Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, et al.
Standardized centile curves and reference intervals of serum insulin-like growth factorI (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J
(2012) 59:771–80. doi: 10.1507/endocrj.ej12-0110
34. De Bellis A, Dello Iacovo A, Bellastella G, Savoia A, Cozzolino D, Sinisi AA, et al.
Characterization of pituitary cells targeted by antipituitary antibodies in patients with
isolated autoimmune diseases without pituitary insufficiency may help to foresee the
kind of future hypopituitarism. Pituitary (2014) 17:457–63. doi: 10.1007/s11102-0130526-9
18. US Department of Health and Human Services. Common terminology criteria for
adverse events. Version 5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/
electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf (2020).
35. Labadzhyan A, Wentzel K, Hamid O, Chow K, Kim S, Piro L, et al. Endocrine
autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: A
prospective study. J Clin Endocrinol Metab (2022) 107:1976–82. doi: 10.1210/clinem/
dgac161
19. Ono M, Fukuda I, Nagao M, Tomiyama K, Okazaki-Hada M, Shuto Y, et al. HLA
analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH
deficiency. Pituitary (2022) 25:615–21. doi: 10.1007/s11102-022-01231-1
Frontiers in Immunology
09
frontiersin.org
...
論文の公開元へ
